ConductScience.org, home
A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma
API referenceFor AI assistants

Trial · NCT05564052

Participant flow16

How many started, completed or left each group, period by period.

1 to 16 of 16

Download this page as JSON
PeriodMilestoneGroupParticipantsUnits counted
Overall StudySTARTEDArm A1: Ibrutinib 560 mg + Rituximab 375 mg/m^210
Overall StudySTARTEDArm A2: Ibrutinib 420 mg + Rituximab 375 mg/m^29
Overall StudySTARTEDArm A3: Ibrutinib 140 mg + Rituximab 375 mg/m^28
Overall StudySTARTEDArm B: Lenalidomide 20 mg (or 10 mg if CrCl Was 30 to <60 mL/Min) + Rituximab 375 mg/m^29
Overall StudyParticipants Who Switched to Ibrutinib MonotherapyArm A1: Ibrutinib 560 mg + Rituximab 375 mg/m^20
Overall StudyParticipants Who Switched to Ibrutinib MonotherapyArm A2: Ibrutinib 420 mg + Rituximab 375 mg/m^24
Overall StudyParticipants Who Switched to Ibrutinib MonotherapyArm A3: Ibrutinib 140 mg + Rituximab 375 mg/m^23
Overall StudyParticipants Who Switched to Ibrutinib MonotherapyArm B: Lenalidomide 20 mg (or 10 mg if CrCl Was 30 to <60 mL/Min) + Rituximab 375 mg/m^22
Overall StudyCOMPLETEDArm A1: Ibrutinib 560 mg + Rituximab 375 mg/m^210
Overall StudyCOMPLETEDArm A2: Ibrutinib 420 mg + Rituximab 375 mg/m^29
Overall StudyCOMPLETEDArm A3: Ibrutinib 140 mg + Rituximab 375 mg/m^28
Overall StudyCOMPLETEDArm B: Lenalidomide 20 mg (or 10 mg if CrCl Was 30 to <60 mL/Min) + Rituximab 375 mg/m^28
Overall StudyNOT COMPLETEDArm A1: Ibrutinib 560 mg + Rituximab 375 mg/m^20
Overall StudyNOT COMPLETEDArm A2: Ibrutinib 420 mg + Rituximab 375 mg/m^20
Overall StudyNOT COMPLETEDArm A3: Ibrutinib 140 mg + Rituximab 375 mg/m^20
Overall StudyNOT COMPLETEDArm B: Lenalidomide 20 mg (or 10 mg if CrCl Was 30 to <60 mL/Min) + Rituximab 375 mg/m^21

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT05564052/flow

API referenceFor AI assistants